Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 1;178(2):117-124.
doi: 10.1001/jamapediatrics.2023.5082.

Prophylactic Oropharyngeal Surfactant for Preterm Newborns at Birth: A Randomized Clinical Trial

Madeleine C Murphy  1   2   3 , Jan Miletin  4 , Claus Klingenberg  5   6 , Hans Jørgen Guthe  7 , Vincent Rigo  8 , Richard Plavka  9 , Kajsa Bohlin  10   11 , Almerinda Barroso Pereira  12 , Tomáš Juren  13 , Ekele Alih  2 , Marie Galligan  14 , Colm P F O'Donnell  1   2
Affiliations

Prophylactic Oropharyngeal Surfactant for Preterm Newborns at Birth: A Randomized Clinical Trial

Madeleine C Murphy et al. JAMA Pediatr. .

Abstract

Importance: Preterm newborns at risk of respiratory distress syndrome are supported with continuous positive airway pressure (CPAP). Many newborns worsen despite CPAP and are intubated for surfactant administration, an effective therapy for treatment of respiratory distress syndrome. Endotracheal intubation is associated with adverse effects. Pharyngeal administration of surfactant to preterm animals and humans has been reported as an alternative.

Objective: To assess whether giving prophylactic oropharyngeal surfactant to preterm newborns at birth would reduce the rate of intubation for respiratory failure.

Design, setting, and participants: This unblinded, parallel-group randomized clinical trial (Prophylactic Oropharyngeal Surfactant for Preterm Infants [POPART]) was conducted from December 17, 2017, to September 11, 2020, at 9 tertiary neonatal intensive care units in 6 European countries. Newborns born before 29 weeks of gestation without severe congenital anomalies, for whom intensive care was planned, were eligible for inclusion. The data were analyzed from July 27, 2022, to June 20, 2023.

Intervention: Newborns were randomly assigned to receive oropharyngeal surfactant at birth in addition to CPAP or CPAP alone. Randomization was stratified by center and gestational age (GA).

Main outcomes and measures: The primary outcome was intubation in the delivery room for bradycardia and/or apnea or in the neonatal intensive care unit for prespecified respiratory failure criteria within 120 hours of birth. Caregivers were not masked to group assignment.

Results: Among 251 participants (mean [SD] GA, 26 [1.5] weeks) who were well matched at study entry, 126 (69 [54.8%] male) with a mean (SD) birth weight of 858 (261) grams were assigned to the oropharyngeal surfactant group, and 125 (63 [50.4%] male) with a mean (SD) birth weight of 829 (253) grams were assigned to the control group. The proportion of newborns intubated within 120 hours was not different between the groups (80 [63.5%) in the oropharyngeal surfactant group and 81 [64.8%] in the control group; relative risk, 0.98 [95% CI, 0.81-1.18]). More newborns assigned to the oropharyngeal surfactant group were diagnosed with and treated for pneumothorax (21 [16.6%] vs 8 [6.4%]; P = .04).

Conclusions and relevance: This randomized clinical trial found that administration of prophylactic oropharyngeal surfactant to newborns born before 29 weeks' GA did not reduce the rate of intubation in the first 120 hours of life. These findings suggest that administration of surfactant into the oropharynx immediately after birth in addition to CPAP should not be routinely used.

Trial registration: EudraCT: 2016-004198-41.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Murphy reported receiving grants from the University College Dublin (UCD) Clinical Research Centre during the conduct of the study. Prof Klingenberg reported receiving funding from Chiesi Farmaceutici and receiving honoraria for being a member of the board of a Nordic Neonatal Meeting outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. CONSORT Diagram
CONSORT indicates Consolidated Standards of Reporting Trials and CPAP, continuous positive airway pressure.
See this image and copyright information in PMC

Comment in

References

    1. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child. 1959;97(5, pt 1):517-523. doi:10.1001/archpedi.1959.02070010519001 - DOI - PubMed
    1. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980;1(8159):55-59. doi:10.1016/S0140-6736(80)90489-4 - DOI - PubMed
    1. Enhorning G, Shennan A, Possmayer F, Dunn M, Chen CP, Milligan J. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. Pediatrics. 1985;76(2):145-153. doi:10.1542/peds.76.2.145 - DOI - PubMed
    1. Ten Centre Study Group . Ten Centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. BMJ (Clin Res Ed). 1987;294(6578):991-996. doi:10.1136/bmj.294.6578.991 - DOI - PMC - PubMed
    1. Merritt TA, Hallman M, Bloom BT, et al. . Prophylactic treatment of very premature infants with human surfactant. N Engl J Med. 1986;315(13):785-790. doi:10.1056/NEJM198609253151301 - DOI - PubMed

Publication types

Substances